Remove 2022 Remove Access Remove DEA Remove Programs
article thumbnail

Americans Will Cultivate Over 4 Billion Grams Of Homegrown Cannabis in 2022

Veriheal

Despite the federal illegality of cannabis, lawmakers and state representatives have implemented successful medical and recreational cannabis programs across the nation. As of July 2022, 38 states in America have legalized medical cannabis, and 19 states and the District of Columbia have established recreational cannabis programs.

article thumbnail

How to access and assess ketamine therapy options

The Cannigma

While costs to access ketamine therapy can be high in some locations, and like any drug ketamine is not a cure-all, some patients and their doctors have been reporting life-changing results when no other treatment provided relief. What is treatment like through an at-home ketamine program? At-home ketamine treatment programs vary.

Therapy 78
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabis Trends of 2022

Kind Meds (Cannabis Education Blog)

Review our compilation of cannabis trends for 2022 to stay up to date on the latest news in the cannabis industry and ensure you are prepared for the future. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

article thumbnail

The Week in Weed: January 19, 2024

The Blunt Truth

HHS DOCUMENT RELEASE Last month , the Department of Health and Human Services (HHS) released a heavily redacted version of their recommendation to the Drug Enforcement Administration (DEA) that cannabis be moved from Schedule I to Schedule III. Of course, the DEA will make its own decision, as we noted earlier this month.

DEA 59
article thumbnail

U.S. Cannabis Legalization Update: Who’s Still Waiting and Who May Legalize

Veriheal

The Act aimed to provide patients access to smokable flower for 15 medical conditions. However, the state’s legislative landscape is evolving, with the passage of a bill to fully legalize medical cannabis in 2022. Wisconsin Wisconsin has no state medical cannabis program and no licensed medical Marijuana dispensaries.

article thumbnail

Canopy Growth Reports First Quarter Fiscal 2022 Financial Results – The John Bonham Of Cannabis?

Cannabis Law Report

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).

Vaping 105
article thumbnail

Dales Report: 10 Psychedelic Companies To Watch In 2022

Cannabis Law Report

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November.